Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune lymphoproliferative syndrome.

Michael C Sneller1, Janet K Dale, Stephen E Straus

  • 1Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. sneller@nih.gov

Current Opinion in Rheumatology
|June 24, 2003
PubMed
Summary

Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder affecting programmed cell death in lymphocytes. Mutations, often in the Fas protein, disrupt immune homeostasis, leading to autoimmune disease and enlarged lymph nodes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological Manifestations in Adult Survivors of Ebola Virus Disease.

JAMA neurology·2026
Same author

Correlations among quantitative assays that measure the size of HIV reservoirs in people with HIV receiving antiretroviral therapy.

AIDS (London, England)·2025
Same author

Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.

Nature medicine·2025
Same author

Timing of antiretroviral therapy initiation affects intact HIV reservoirs following analytical treatment interruption.

The Journal of clinical investigation·2024
Same author

Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.

EBioMedicine·2024
Same author

Pandemic-Related Post-traumatic Stress Symptomatology in COVID-19 Patients with and without Post-COVID Conditions.

medRxiv : the preprint server for health sciences·2024

Area of Science:

  • Immunology
  • Genetics
  • Cell Biology

Background:

  • Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder characterized by impaired lymphocyte apoptosis (programmed cell death).
  • Defective apoptosis disrupts immune homeostasis, leading to lymphadenopathy, splenomegaly, autoimmune manifestations, and expansion of unusual T cell populations (CD4-CD8-).
  • Mutations in genes regulating lymphocyte apoptosis, particularly the Fas (CD95, Apo1) protein, are implicated in most ALPS cases.

Purpose of the Study:

  • To summarize the key features and genetic underpinnings of Autoimmune Lymphoproliferative Syndrome (ALPS).
  • To highlight the role of defective lymphocyte apoptosis in ALPS pathogenesis.
  • To underscore the expanding spectrum of ALPS and its complications.

Main Methods:

Related Experiment Videos

  • Review of prospective evaluations of ALPS patients and their families.
  • Analysis of genetic mutations affecting lymphocyte apoptosis pathways.
  • Clinical and immunological characterization of affected individuals.

Main Results:

  • ALPS is caused by inherited mutations in genes controlling lymphocyte apoptosis.
  • Heterozygous mutations in the Fas protein are common, impairing a critical apoptotic pathway.
  • Clinical manifestations include chronic lymphadenopathy, splenomegaly, autoimmune diseases, and a distinct CD4-CD8- T cell population.

Conclusions:

  • Defective lymphocyte apoptosis due to genetic mutations is the central mechanism in ALPS.
  • The spectrum of ALPS and its associated autoimmune complications is continually being defined.
  • Understanding these genetic defects is crucial for diagnosing and managing ALPS.